

# INDEX

---

## A

### Adhesions,

- anti-adhesion clinical trial design,
  - control group, 238, 239
  - critical questions, 234, 239
  - endpoints, 234, 235
  - imputation of data in Intergel® trial, 246–248
  - inclusion and exclusion criteria, 237, 238
  - investigative center recruitment, 238
  - investigator selection, 235
  - patient population, 235, 236
  - scoring of adhesions, 236, 237
  - standardization of procedure, 238
  - surgical site access, 236
- consequences, 233, 234
- incidence, 233

## B

### Babe Ruth effect, drugs and medical devices, 192, 193

### Bayesian methodology,

- Bayes risk, 107
- borrowing strength,
  - intercenter trials, 104, 105
  - previous studies, 103, 104
- clinical trial design and analysis,
  - controls, 109, 110
  - effectiveness claims with active controls, 109
  - interim analysis and midcourse modifications, 110, 111
  - missing data, 113, 114, 120, 121
- multiplicity,
  - multiple endpoints, 112, 113
  - patient subsets, 112

- noninferiority claims, 109
- sample size, 110
- superiority claims, 108, 109
- exchangeability, 102, 103
- frequentist approach comparison, 107
- imputation, *see* Missing data
- likelihood principle, 106
- posterior distribution, 99, 101, 102
- predictive distributions,
  - clinical outcome prediction from surrogate, 105
  - early termination of trial, 105
  - labeling and medical decision making, 105
  - missing data prediction, 106
- prior distribution, 99–101
- Beall heart valve, retrieval studies, 319–321
- BELIEF trial,
  - baseline tests and assessments, 222, 224
  - blinding and randomization, 217, 222, 224, 230
  - Cardiogenesis Axcis percutaneous myocardial laser system, 220
  - ejection fractions, 229
  - exercise testing, 229
  - financial sponsors, 219
  - follow-up, 223, 227
  - medication usage, 229
  - participating institutions, 220
  - patient selection, 220, 221, 225, 230
  - primary endpoints, 220, 227, 228, 230, 231

- procedural outcomes, 225
- quality of life, 229
- statistical analysis, 221
- technique, 222, 223
- Björk-Shiley convexo-concave
  - heart valve, retrieval studies, 315–318
- Braunwald-Cutter cloth-covered
  - heart valve, retrieval studies, 311, 312, 315
- C**
- Carbomedics photo-fix pericardial
  - heart valve, retrieval studies, 323
- Cardiac pacemaker,
  - components, 286, 287
  - implant procedure, 287
  - polyurethane leads,
    - development and market release, 289
    - encapsulation, 295
    - environmental stress cracking failure,
      - mechanism, 290–292
      - reoperation rates, 290, 292
      - testing, 293
    - metal ion oxidation,
      - mechanisms, 293, 294
      - testing, 294
    - postmarket surveillance,
      - chronic study development, 295–298
      - crush fracture mechanism, 300, 301, 303
      - data analysis, 299, 300
      - returned product analysis, 295, 301, 302
      - rationale for use, 287–289
- Cardiogenesis Axcis percutaneous myocardial laser system, *see* BELIEF trial
- Case report, forms, 17
- Clinical trial design,
  - analytical studies, 12
  - anti-adhesion adjuvants, *see* Adhesions
  - Bayesian methods, *see* Bayesian methodology
  - challenges for medical devices,
    - blinding inability, 7
    - drugs vs devices, 4, 5
    - implantation, 7, 8
    - innovation frequency, 7
    - left ventricular assist devices, *see* Left ventricular assist device
  - overview, 3, 4
  - small companies as manufacturers, 8
  - training, 6, 7
  - transmyocardial
    - revascularization, *see* Transmyocardial laser revascularization
- elements of investigational plan, *see* Investigational plan elements
- HIPAA compliance, *see* Health Insurance Portability and Accountability Act
- missing data, *see* Missing data
- observational studies, 11
- product development,
  - pilot studies, 8, 9
  - pivotal trials, 9, 10
  - postmarket studies, 10, 11
- surrogate endpoint, *see* Surrogate outcome measure
- Combination products (CPs),
  - classification or designation, 162, 164–166
- CYPHER™ Sirolimus-Eluting
  - Coronary Stent case study, 161, 168–171
  - development program, 166–168, 182

- drug-coated occlusion coil, 164–166
- nonapproved device product development issues, 175, 176
- novel chemical entity product development issues, Canada, 179, 180 Europe, 176–179 radiopharmaceuticals, 173–175 study requirements, 171–173 prospects for development, 182 regulatory oversight, 163 start-up company challenges, 181, 182
- Competitive advantage, sustainability, 187, 193, 194
- Control group, investigational plan, 14, 15
- Cooper Committee, distinguishing drugs vs devices, 4, 5
- Copyright, medical device protection, 119, 120 utility patent comparison, 135
- Corneal pachymetry, local coverage determination, 263, 264
- Corporate merger, medical device companies, 193
- CPs, *see* Combination products
- CPT-4 codes, Medicare usage, 73–75, 271
- CYPHER™ Sirolimus-Eluting Coronary Stent, case study of combination product development, 161, 168–171
- D**
- Diagnosis-related group (DRG), Medicare reimbursement, 69–71
- DRG, *see* Diagnosis-related group
- Drug–device combination products, *see* Combination products
- E**
- Endpoints, investigational plan, 15 surrogate, *see* Surrogate outcome measure
- Evidence-based medicine, local coverage determination role, 257, 258
- Exogen Sonic Accelerated Fracture Healing System® (SAFHS), approval for market, 271, 272 reimbursement case study, lessons learned, 279–282 medical director questions, 273 Medicare, 274–279 private payers, 274, 275 reasonable and necessary requirement, 272, 273
- F**
- Fabrazyme®, imputation of trial data, 248, 249
- FDA, *see* Food and Drug Administration
- Financial disclosure, Food and Drug Administration regulation, 25
- Food and Drug Administration (FDA), clinical trial regulation, financial disclosure requirements, 25 Institutional Review Board, 26 investigators, 24–26 sponsors and sponsorship transfer, 23, 24 exportation of unapproved devices for investigational use, 49, 50
- Health Insurance Portability and Accountability Act impact, 149

- human subject regulations, 143, 144
  - investigational device exemption, *see* Investigational device exemption
  - in vitro diagnostic device regulation, 47
  - postmarket requirements, *see* Postmarket regulation
  - valid scientific evidence and international studies, 48, 49
- H**
- Health Insurance Portability and Accountability Act (HIPAA), authorization for protected health information disclosure, core elements, 144
  - deceased individuals, 145
  - limited data sets, 146, 147
  - waiver or alteration, 145, 146
  - clinical research effects, existing data banks or repositories, 149, 150
  - Food and Drug Administration, 149
  - preparatory activities, 149
  - researcher attitudes, 150
  - tracking, 149
  - Common Rule regulation comparison, 143, 144
  - de-identifying protected health information, 147–149
  - historical perspective, 141, 142
  - Privacy Rule, 142, 143
  - Heartmate® left ventricular assist device, *see* REMATCH trial
  - Heart valve prostheses, historical perspective, 305
  - retrieval and pathologic analysis, animal studies, 310
  - calcification failure, 318, 319
  - case studies, allograft valves, 321, 322
  - Beall heart valve, 319–321
  - Björk-Shiley convexo-concave heart valve, 315–318
  - Braunwald-Cutter cloth-covered heart valve, 311, 312, 315
  - Carbomedics photo-fix pericardial heart valve, 323
  - Medtronic Parallel Bileaflet Heart Valve, 322, 323
  - challenges, 323, 324
  - clinical studies, 310, 311
  - general considerations, 307–310
  - objectives, 308, 309
  - successful study features, 308, 309
  - HIPAA, *see* Health Insurance Portability and Accountability Act
- I**
- ICD-9-CM codes, Medicare usage, 75
  - IDE, *see* Investigational device exemption
  - Imputation, *see* Missing data
  - Informed consent, exception in emergency research, 35, 36
  - forms, 16, 17
  - investigational device exemption requirement, 34, 35
  - protected health information disclosure, 144, 145
  - Innovation, economic reward with medical devices, 191, 192
  - fitness, 193–195
  - investing principles, 195, 196
  - Institutional Review Board (IRB), approval, 17
  - definition, 26

- Food and Drug Administration
  - regulation, 26
  - protected health information
    - disclosure, 145, 146
- Intellectual property (IP),
  - copyright, 119, 120
  - nondisclosure agreements, 138
  - overview, 117, 118
  - patent,
    - application, 129, 130
    - claims, 129
    - coinventors, 137
    - copyright comparison, 135
    - design vs utility patents, 134
    - drawings, 129
    - foreign countries, 139
    - format, 121
    - invalidation, 137
    - marking, 137, 138
    - opinion letter, 136
    - patentability of device, 117, 119, 132–134
    - patent examiners, 130–132
    - patent office confidentiality, 136, 137
    - patent pending, 136
    - patent prosecution, 131, 132
    - patient infringement, 135, 136
    - publication considerations, 134
    - sample, 121–123, 125–128
    - statutory bar activities, 134
    - written description, 121, 123, 124, 128
  - trade secret, 120
  - trademark, 119
- Intergel®, *see* Adhesions
- International Organization for Standardization (ISO), European medical device regulation, 48
- Investigational device exemption (IDE),
  - application,
    - approval process, 26, 27
    - disapproval or withdrawal, 32, 33
    - modifications, 31, 32
    - nonsignificant risk devices
      - and abbreviated requirements, 30
    - pre-investigational device
      - exemption meetings,
      - formal guidance meetings, 27, 28
      - informal guidance meetings, 27
    - pre-investigational device submissions, 28
    - significant risk devices,
      - requirements, 30, 31
      - vs nonsignificant risk devices, 29, 30
  - closing procedures, 33
  - exempt devices, 22
  - exportation of unapproved devices
    - for investigational use, 49, 50
- Food and Drug Administration
  - regulation, 22, 23, 26–33
  - historical perspective, 21, 22
  - Medicare coverage, 65, 66
  - patient access to unapproved medical devices,
    - compassionate use, 44
    - continued access policy, 46
    - emergency use, 42, 44
    - treatment use, 44–46
  - postmarket requirements, *see* Postmarket regulation
  - promotion prohibition, 39, 41, 42
  - study requirements,
    - informed consent, 34–36
    - monitoring, 36
    - records and reports, 36–39
- Investigational plan elements,
  - case report forms, 17
  - control group, 14, 15
  - data analysis plan, 16

- data safety monitoring board, 17
- device description, 13
- endpoints for effectiveness and safety, 15
- informed consent forms, 16, 17
- investigational sites and Institutional Review Board approval, 17
- investigator's brochure, 17
- monitoring plan, 18
- overview, 12
- risk analysis, 16
- sample-size calculation, 16
- study design, 13
- study objective, 13
- study population, 13
- study procedures and duration, 16
- success definition, 15
- treatment regimen, 14
- Investigator,
  - definition, 24, 25
  - disqualification, 25, 26
  - Food and Drug Administration regulation, 24–26
  - general responsibilities, 25
  - record keeping, 38
- In vitro diagnostic device (IVD),
  - definition, 47
  - Food and Drug Administration regulation, 47
- IP, *see* Intellectual property
- IRB, *see* Institutional Review Board
- ISO, *see* International Organization for Standardization
- IVD, *see* In vitro diagnostic device
- L**
- Laser optic coherence tomography (LOCT), local coverage determination, 262, 263
- LCD, *see* Local coverage determination
- Left ventricular assist device (LVAD),
  - heart failure epidemiology and management, 200
  - historical perspective, 200
  - prospects for development, 210–213
- REMATCH trial,
  - adverse events, 207, 208
  - approval of device, 209, 210
  - baseline characteristics, 206
  - costs, 208
  - Heartmate® system
    - overview, 201
  - hospital stay duration, 208
  - organization and funding, 203
  - patient selection, 203, 204
  - PREMATCH pilot study, 202, 203
  - quality of life, 207, 209
  - statistical design, 204, 205
  - study design, 204
  - survival, 206, 207, 209
  - risk categorization, 199
- Limited data set, protected health information disclosure, 146, 147
- Local coverage determination (LCD), *see* Medicare
- LOCT, *see* Laser optic coherence tomography
- LVAD, *see* Left ventricular assist device
- M**
- Medical device, definition, 3
- Medical device reporting, *see* Postmarket regulation
- Medicare, *see also* Reimbursement
  - appealing of claims, 276, 277
  - benefit categories and statutory limitations, 61
  - clinical trial coverage,
    - Category B investigational devices, 158, 159
  - impact on patients and researchers, 159
  - overview, 66, 153, 154

- routine cost policy,
  - clinical trial requirements, 154–156
  - non-qualifying services, 156, 157
  - origins, 154
  - qualifying services, 157, 158
- coding,
  - CPT-4 codes, 73–75, 271
  - Healthcare Common Procedure Coding System, 73–75
  - ICD-9-CM codes, 75
- coverage interpretation by Centers for Medicare and Medicaid Services and contractors, 61–63
- Exogen Sonic Accelerated Fracture Healing System® case study of reimbursement, 274–279
- home prothrombin monitoring coverage, 333
- local coverage determination by contractors,
  - balance of factors in decision-making, 258–260
  - case studies,
    - corneal pachymetry, 263, 264
    - laser optic coherence tomography, 262, 263
    - molecular diagnostics for infectious diseases, 260–262
    - off-label oncology drug coverage, 265
    - ophthalmologic diagnostic testing, 262
    - osteoporosis screening, 260
    - wireless capsule endoscopy, 264, 265
  - evidence-based medicine role, 257, 258
  - overview, 256, 257
- medical device coverage,
  - clinical trials, 66
  - individualized determinations, 65
  - investigational devices, 65, 66
  - limitations, 66, 67
  - local coverage determination, 64, 65, 254, 255
  - national coverage determination, 63, 64, 254, 255
- origins, 59
- reimbursement,
  - fee schedules, 68
  - medical devices in specific settings,
    - acute care hospitals, 69–71
    - home care, 72, 73
    - hospital outpatients, 71, 72
    - physician offices and clinics, 72
  - prospective payment system, 68
  - reasonable costs, 68, 69
- spending, 59
- statutory authority, 60, 61
- time required for systemic changes, 271
- Medtronic Parallel Bileaflet Heart Valve, retrieval studies, 322, 323
- Missing data,
  - causes, 241
  - imputation,
    - examples,
      - Fabrazyme® trial, 248, 249
      - Intergel® trial, 246–248
      - National Medical Expenditure Survey data, 249, 250
    - multiple imputation,
      - combining rules, 245, 246
      - computation, 246
      - overview, 245

- single imputation,
  - monotone missingness, 244
  - nonmonotone missingness, 244, 245
  - overview, 242, 243
  - software for analysis, 241
- mechanisms,
  - missing completely at random, 242
  - missing at random, 242
  - not missing at random, 242
- prediction in Bayesian methodology, 106, 113, 114
- Molecular diagnostics, local coverage determination, 260–262
- Monitoring plan, investigational plan, 18
- Multiplicity, *see* Bayesian methodology
- N**
- National coverage determination (NCD), Medicare, 63, 64, 254, 255
- National Medical Expenditure Survey (NMES), imputation of data, 249, 250
- NCD, *see* National coverage determination
- NDA, *see* Nondisclosure agreement
- New technology life cycle,
  - curve amplitude and market opportunity, 189, 190
  - curve slope and length of product cycle, 190, 191
  - growth, 189
  - introduction, 188, 189
  - maturity, 189
  - proof of concept, 188
  - survival, 189
- Nondisclosure agreement (NDA), intellectual property protection, 138
- Nonsignificant risk devices, investigational device exemption, 29, 30
- Notification,
  - mandatory vs voluntary, 92
  - repair, replacement, or refund, 92, 93
- O**
- Ophthalmologic diagnostic testing, local coverage determination, 262
- Osteoporosis screening, local coverage determination, 260
- P**
- Pacemaker, *see* Cardiac pacemaker
- Patent,
  - application, 129, 130
  - claims, 129
  - coinventors, 137
  - copyright comparison, 135
  - design vs utility patents, 134
  - drawings, 129
  - foreign countries, 139
  - format, 121
  - invalidation, 137
  - marking, 137, 138
  - opinion letter, 136
  - patentability of device, 117, 119, 132–134
  - patent examiners, 130–132
  - patent office confidentiality, 136, 137
  - patent pending, 136
  - patent prosecution, 131, 132
  - patient infringement, 135, 136
  - publication considerations, 134
  - sample, 121–123, 125–128
  - statutory bar activities, 134
  - written description, 121, 123, 124, 128
- Percutaneous transluminal coronary angioplasty (PTCA), transition from bypass grafting, 191, 195
- Posterior distribution, *see* Bayesian methodology



- Postmarket regulation,  
adverse reaction and device  
defect reporting, 82, 83  
cardiac pacemaker polyurethane  
lead surveillance case study,  
chronic study development,  
295–298  
crush fracture mechanism,  
300, 301, 303  
data analysis, 299, 300  
returned product analysis,  
295, 301, 302  
challenges with medical devices,  
10, 11  
complaint files, 82  
Health Insurance Portability and  
Accountability Act  
impact, 149  
legislative authorization, 81  
medical device reporting,  
adverse event reporting,  
mandatory requirements,  
85, 87  
voluntary requirements, 87  
baseline and annual reports, 87  
becoming aware of adverse  
event information, 84  
caused or contributed clause, 84  
corrections and removals,  
87, 88  
public disclosure of records, 88  
record-keeping, 85  
reportable events, 83, 84  
serious injury, 84, 85  
notification,  
mandatory vs voluntary, 92  
repair, replacement, or refund,  
92, 93  
recalls,  
mandatory, 94  
voluntary, 93, 94  
role, 81, 82  
surveillance,  
mandated studies, 91  
voluntary studies, 91, 92  
tracking of devices,  
criteria, 89  
device types, 89  
distributors and user facilities,  
90  
historical perspective, 88  
manufacturers, 90  
patient issues, 90  
Pricing, medical devices, 190  
Prior distribution, *see* Bayesian  
methodology  
Privacy Board, protected health infor-  
mation disclosure, 145, 146  
Prothrombin time, home prothrom-  
bin monitoring, 332–334  
PTCA, *see* Percutaneous transluminal  
coronary angioplasty
- R**
- Recall,  
mandatory, 94  
voluntary, 93, 94  
Reimbursement, *see also* Medicare  
establishment in product devel-  
opment, 269, 271  
Exogen Sonic Accelerated Frac-  
ture Healing System® case  
study,  
lessons learned, 279–282  
medical director questions, 273  
Medicare, 274–279  
private payers, 274, 275  
reasonable and necessary  
requirement, 272, 273  
product classification implica-  
tions, 269–271  
strategy establishment to achieve  
company objectives,  
282, 283  
REMATCH trial,  
adverse events, 207, 208  
approval of device, 209, 210  
baseline characteristics, 206  
costs, 208  
Heartmate® system overview, 201  
hospital stay duration, 208

- organization and funding, 203
- patient selection, 203, 204
- PREMATCH pilot study, 202, 203
- quality of life, 207, 209
- statistical design, 204, 205
- study design, 204
- survival, 206, 207, 209
- Risk analysis, investigational plan, 16
- S**
- SAFHS, *see* Exogen Sonic Accelerated Fracture Healing System®
- Significant risk device,
  - investigational device exemption, 29–31
  - postmarket requirements, *see* Postmarket regulation
- Sponsor,
  - Food and Drug Administration regulation, 23, 24, 39
  - reports, 39–41
- Surrogate outcome measure,
  - definition, 331, 332
  - home prothrombin monitor case study, 332–334
  - limitations, 332
- Surveillance, *see* Postmarket regulation
- T**
- Technology life cycle, *see* New technology life cycle
- TMR, *see* Transmyocardial laser revascularization
- Tracking, *see* Postmarket regulation
- Trademark, medical device protection, 119
- Trade secret, medical device protection, 120
- Transmyocardial laser revascularization (TMR),
  - BELIEF trial,
    - baseline tests and assessments, 222, 224
    - blinding and randomization, 217, 222, 224, 230
  - Cardiogenesis Axcis percutaneous myocardial laser system, 218, 219
  - ejection fractions, 229
  - exercise testing, 229
  - financial sponsors, 219
  - follow-up, 223, 227
  - medication usage, 229
  - participating institutions, 220
  - patient selection, 220, 221, 225, 230
  - primary endpoints, 220, 227, 228, 230, 231
  - procedural outcomes, 225
  - quality of life, 229
  - statistical analysis, 221
  - technique, 222, 223
- device comparison, 218
- indications, 217
- placebo effect, 217
- V**
- Valid scientific evidence,
  - definition, 48
- W**
- Warfarin, home prothrombin monitoring, 332–334
- Wireless capsule endoscopy, local coverage determination, 264, 265